Last reviewed · How we verify
Escitalopram + Bupropion SR
This combination increases serotonin and norepinephrine signaling in the brain through selective serotonin reuptake inhibition and dopamine/norepinephrine reuptake inhibition.
This combination increases serotonin and norepinephrine signaling in the brain through selective serotonin reuptake inhibition and dopamine/norepinephrine reuptake inhibition. Used for Major depressive disorder, Treatment-resistant depression.
At a glance
| Generic name | Escitalopram + Bupropion SR |
|---|---|
| Also known as | escitalopram, bupropion-SR, escitalopram = Lexapro, bupropion = Wellbutrin, Lexapro |
| Sponsor | National Institute of Mental Health (NIMH) |
| Drug class | SSRI + NDRI combination |
| Target | Serotonin transporter (SERT); Norepinephrine transporter (NET); Dopamine transporter (DAT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that blocks the reuptake of serotonin at the synaptic cleft, increasing serotonin availability. Bupropion SR is a norepinephrine-dopamine reuptake inhibitor (NDRI) that blocks reuptake of norepinephrine and dopamine. Together, they provide complementary monoaminergic effects to treat depression and related mood disorders.
Approved indications
- Major depressive disorder
- Treatment-resistant depression
Common side effects
- Nausea
- Insomnia
- Headache
- Dry mouth
- Dizziness
- Tremor
- Sexual dysfunction
- Sweating
Key clinical trials
- Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People (PHASE4)
- Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
- Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression (NA)
- Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics (PHASE2)
- Combining Medications to Enhance Depression Outcomes (PHASE4)
- Treatment of Mood and Marriage Study (TOMMS) (PHASE1, PHASE2)
- Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Escitalopram + Bupropion SR CI brief — competitive landscape report
- Escitalopram + Bupropion SR updates RSS · CI watch RSS
- National Institute of Mental Health (NIMH) portfolio CI